DB-Tools.com - system comparision
3rd December 2021, Friday
Home > System Comparision

Please Choose another system Click here

Editorial information provided by DB-Tools
System CouchDB AllegroGraph
 Name CouchDB AllegroGraph
 Version 3.3.5 AllegroGraph 6.4.2 [2018-06-18]
 Drawbacks 1 Does not have capabilities present in an RDF data store e.g does not support SparQL NA
 Advantages NA -Database being explicitly pre-structured
-Data to self-define the schema at the time of ingest
-Able to connect concepts, properties, and entities across multiple databases and without further coding to extract new, actionable business insights from your data
 Website apache.couchdb.org www.allegrograph.com,
 Languages Supported .net, C#, Javascript Java, Python, Ruby, Perl, C#, Clojure and Common Lisp
 JSON Support yes yes
 XML Support NA yes
 Brief description Open Source Transactional database with native graph storage and processing -Modern, high-performance, persistent graph database
-Uses efficient memory utilization in combination with disk-based storage, enabling it to scale to billions of quads while maintaining superior performance
-Supports SPARQL, RDFS++ and Prolog reasoning from numerous applications
 Database Model Property Graph Graph Database, A triplestore or RDF store
 Technical Documentation docs.microsoft.com/­en-us/­azure/­cosmos-db franz.com/agraph/support/documentation/current/agraph-introduction.html
 License Community license can be run on 1 node.Enterprise License supports multi-node cluster deployment Commercial
 Cloud-based / SaaS Amazon AMI available, On Prem can be installed No
 Implementation Language Java API Common Lisp
 Operating System Supported Linux , OS X, Windows Windows, Linux, and Mac OS X
 Options for Integration / Access API Rest API Java, Python, Common Lisp and other APIs
 Consistency NA Yes
 Foreign Keys No No
 Streaming Support No Yes
 Data Storage Schema Key Value Store presented as Document DB Yes
 Analytics Support No Yes, AllegroGraph Recognized Among Top 10 Analytics Solution Providers by Pharma Tech Outlook for 2016